Sandoz, a generic and biosimilar medicines company, has signed an agreement to acquire the U.S. biosimilar ranibizumab CIMERLI (ranibizumab-eqrn) from Coherus BioSciences, Inc. for $170 million up front. This is inclusive of a biologics license application, product inventory, ophthalmology sales and field reimbursement talent, as well as access to proprietary commercial software.   Keren Haruvi, President Sandoz North America, said, “I am pleased that we can add another high-value product to t...